Skip to main content Accessibility help
×
Home

Gabexate mesilate hastens recovery from vecuronium-induced neuromuscular blockade

  • H. Hattori (a1), Y. Saitoh (a1), H. Nakajima (a1), N. Sanbe (a1), M. Akatu (a1) and M. Murakawa (a1)...

Extract

Summary

Background and objective: To test the hypothesis that gabexate mesilate, a protease inihibitor, hastens recovery from neuromuscular blockade, we examined the effect of gabexate mesilate on the recovery of vecuronium-induced neuromuscular blockade in anaesthetized patients in a double-blind, randomized fashion.

Methods: Thirty adult patients were divided into two groups of 15. In the gabexate mesilate group, immediately after administration of vecuronium 0.1 mg kg−1, a continuous infusion of gabexate mesilate was started at a speed of 1.5 mg kg−1 h−1. In the control group, normal saline was administered instead of gabexate mesilate. Times to the return of T1, T2, T3 or T4 (first, second, third and fourth response of train-of-four (TOF)), times to the recovery of T1/control to 0.25 (T25) or 0.5 (T50), recovery of T1/control or TOF ratio (T4/T1) were compared between the two groups.

Results: Times to the returns of T1, T2, T3 and T4 in the gabexate mesilate group were significantly shorter than in the control group (19.4 ± 6.8 vs. 25.7 ± 7.2 min for T1; mean ± SD, P = 0.020). Times to T25 and T50 were significantly shorter in the gabexate mesilate group than in the control group (34.0 ± 9.9 vs. 51.3 ± 10.2 min for T25, P < 0.001). T1/control and TOF ratio in the gabexate mesilate group were significantly higher than in the control group 40–80 min and 40–120 min after administration of vecuronium, respectively (P < 0.05).

Conclusion: Gabexate mesilate hastens recovery from neuromuscular block in anaesthetized patients receiving vecuronium.

Copyright

Corresponding author

Correspondence to: Hisashi Hattori, Department of Anesthesiology, Fukushima Medical University School of Medicine, Hikarigaoka 1, Fukushima City, Fukushima 960-1295, Japan. E-mail: hattori@sb.dcns.ne.jp; Tel: +81 24 547 1341; Fax: +81 24 548 0828

References

Hide All

References

Harvey AL, Karlsson E. Protease inhibitor homologues from mamba venoms: facilitation of acetylcholine release and interactions with prejunctional blocking toxins. Br J Pharmacol 1982; 77: 153161.
Mastumoto N, Ohara K, Yoshida N, et al. Protective effects of ulinastatin on hepatic oxygen metabolism during halothane anesthesia in the presence of graded hypoxic hypoxemia. Masui (Jap J Anesthesiol) 1989; 38: 531539.
Harada N, Okajima K, Kushimoto S. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Crit Care Med 1999; 27: 19581964.
Kim YI, Hwang YJ, Song KE, Yun YK, Lee JW, Chun BY. Hepatocyte protection by a protease inhibitor against ischemia/reperfusion injury of human liver. J Am Coll Surg 2002; 195: 4150.
Chen HM, Hwang TL, Chen MF. The effect of gabexate mesilate on pancreatic and hepatic microcirculation in acute experimental pancreatitis in rats. J Surg Res 1996; 66: 147153.
Casson WR, Jones RM. Vecuronium induced neuromuscular blockade. The effect of increasing dose on speed of onset. Anaesthesia 1986; 41: 354357.
Upton RA, Nguyen TL, Miller RD, Castagnoli Jr N. Renal and biliary elimination of vecuronium ORG NC 45 and pancuronium in rats. Anesth Analg 1982; 61: 313316.
Bencini AF, Scaf AHJ, Agoston S, Houwertjes MC, Kersten UW. Disposition of vecuronium in the cat. Br J Anaesth 1985; 57: 782788.
Saitoh Y, Fujii Y, Oshima T. The ulinastatin-induced effect on neuromuscular block caused by vecuronium. Anesth Analg 1999; 89: 15651569.
Saitoh Y, Kaneda K, Murakawa M. The effect of ulinastatin-pretreatment on vecuronium-induced neuromuscular block in patients with hepatic cirrhosis. Anaesthesia 2002; 57: 218222.
Viby-Mogensen J, Engbaek J, Eriksson LI, et al. Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996; 40: 5974.
Lee GC, Iyengar S, Szenohradszky J, et al. Improving the design of muscle relaxant studies. Stabilization period and tetanic recruitment. Anesthesiology 1997; 87: 459460.
Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg 1999; 177: 7882.
Smith CE, van Miert MM, Parker CJ, Hunter JM. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1′R-cis isomer of atracurium, with atracurium besilate in healthy patients. Anaesthesia 1997; 52: 833841.
De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996; 76: 624628.
Xue FS, Liao X, Liu JH, et al. Dose-response curve and time-course of effect of vecuronium in male and female patients. Br J Anaesth 1998; 80: 720724.
Chauvin M, Lebrault C, Duvaldestin P. The neuromuscular blocking effect of vecuronium on the human diaphragm. Anesth Analg 1987; 66: 117122.
Kopman AF. The relationship of evoked electromyographic and mechanical responses following atracurium in humans. Anesthesiology 1985; 63: 208211.
Saitoh Y, Kaneda K, Hattori H, Nakajima H, Murakawa M. Monitoring of neuromuscular block after administration of vecuronium in patients with diabetes mellitus. Br J Anaesth 2003; 90: 480486.
Saitoh Y, Kaneda K, Tokunaga Y, Murakawa M. Infusion of amino acid enriched solution hastens recovery from neuromuscular block caused by vecuronium. Br J Anaesth 2001; 86: 814821.
Nishijima MK, Takezawa J, Taenaka N, Shimada Y, Yoshiya I. Application of HPLC measurement of plasma concentration of gabexate mesilate. Thromb Res 1983; 31: 279284.

Keywords

Gabexate mesilate hastens recovery from vecuronium-induced neuromuscular blockade

  • H. Hattori (a1), Y. Saitoh (a1), H. Nakajima (a1), N. Sanbe (a1), M. Akatu (a1) and M. Murakawa (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed